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Dumping syndrome is a frequent complication of can-
cer and non- cancer oesophageal and gastric surgery, as 
well as bariatric surgery (also known as metabolic sur-
gery). These interventions change gastric anatomy and 
innervation, which can enable a considerable amount 
of undigested food to reach the small intestine too rap-
idly1–4. Dumping syndrome comprises a constellation 
of symptoms that can be subdivided into early and late 
dumping syndrome symptoms, which can occur jointly 
or separately1–8. Typically, symptoms of early dumping 
syndrome occur within the first hour after a meal and 
include gastrointestinal symptoms (abdominal pain, 
bloating, borborygmi, nausea and diarrhoea) and vaso-
motor symptoms (flushing, palpitations, perspiration, 
tachycardia, hypotension, fatigue, desire to lie down and, 
rarely, syncope)1,2. The underlying mechanisms might 
involve osmotic effects, peptide hormone release and 
autonomic neural responses1. Symptoms of late dump-
ing syndrome usually occur between 1 and 3 h after a 
meal and are primarily the manifestations of hypogly-
caemia, which mainly results from an incretin- driven 
hyperinsulinaemic response after carbohydrate inges-
tion. Hypoglycaemia- related symptoms are attribut-
able to neuroglycopenia (which is indicated by fatigue, 
weakness, confusion, hunger and syncope) and to vagal 
and sympathetic activation (indicated by perspiration, 
palpitations, tremor and irritability)1,2. The literature has 
referred to late dumping syndrome as ‘reactive hypo-
glycaemia’ or, after bariatric surgery, as ‘postbariatric 
hypoglycaemia’. However, on the basis of a common 
pathophysiology of rapid exposure of the small intes-
tine to nutrients, which is also seen in early dumping 
syndrome (see subsequent discussion), we refer to this 
phenomenon as ‘late dumping syndrome’.
The prevalence of dumping syndrome depends on 
the type and extent of surgery, and on the criteria used 
to diagnose dumping syndrome. Dumping syndrome 
occurs in approximately 20% of patients undergoing 
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vagotomy with pyloroplasty, in up to 40% of patients 
after Roux- en- Y gastric bypass (RYGB) or sleeve 
gastrectomy and in up to 50% of patients under-
going oesophagectomy5,6,9–11. Furthermore, dumping 
syndrome might also occur after Nissen fundoplica-
tion12,13. According to reports published in the past 
15 years, bariatric surgery has become the main cause 
of postoperative dumping syndrome14,15. Dumping 
syndrome has mainly been reported after RYGB and 
partial gastrectomy12,13, but might also occur after 
restrictive bariatric procedures such as sleeve gastrec-
tomy, vertical banded gastroplasty and the laparoscopic 
adjustable gastric band, which all reduce the volume 
capacity of the proximal stomach4. The rapid expan-
sion in the use of bariatric interventions has therefore 
led to an increasing number of patients with dumping 
syndrome16.
Symptoms of dumping syndrome are often debili-
tating and emotionally distressing, they are associated 
with a substantial reduction in quality of life and might 
lead to considerable weight loss as a result of the patient 
avoiding food intake17. In spite of its effects, guidance 
is lacking on how to diagnose this condition, which is 
probably under- recognized. Moreover, established effi-
cacious treatment options and management guidelines 
are lacking in the literature. Therefore, we used a Delphi 
consensus1,9,10,17,18 process to develop uniform guidance 
about the definition, diagnosis and management of 
dumping syndrome.
Methods
The process was coordinated by a chair (J.T.) and a 
co- chair (E.S.), referred to as the chairs. The principal 
steps in the process were, first, selection of a Consensus 
Group consisting of international experts in dumping 
syndrome management with different clinical and scien-
tific backgrounds. Second, draft statements were devel-
oped by the chairs and were refined by the Consensus 
Group after a preliminary voting round with feedback 
on the statements. Third, each expert was assigned to 
contribute to literature reviews on several topics to sum-
marize the evidence to support each statement. Fourth, 
two rounds of online voting of the statements (and vot-
ing discussion) were undertaken until a stable level of 
consensus was reached. Fifth, grading of the strength 
and quality of the evidence and of the strength of the 
recommendations using grading of recommendations, 
assessment, development and evaluation (GRADE) 
criteria was conducted19. Agreement levels were deter-
mined as follows: A+, agree strongly; A, agree with 
minor reservation; A−, agree with major reservation; 
D−, disagree with major reservation; D, disagree with 
minor reservation; D+, disagree strongly.
For the Consensus Group, 18 multidisciplinary 
international experts (gastroenterologists, internists, 
nutritionists, surgeons and endocrinologists) from 
ten countries (Austria, Belgium, France, Greece, Italy, 
Japan, Netherlands, Sweden, Turkey and USA) were 
selected based on their participation in clinical trials 
and publications on dumping syndrome.
A literature research was conducted using a number 
of relevant keywords (medical subject headings (MeSH): 
dumping syndrome, hypoglycaemia and bariatric sur-
gery). The chairs reviewed the list of publications and 
the relevant ones were stored in PDF format on a central 
server to which all Delphi panel members had access. 
The references cited in this paper are only a selection of 
the reviewed articles, chosen to clarify the discussion.
The chairs developed the initial 66 statements that 
were presented to the Consensus Group, who sub-
sequently revised, expanded and consolidated the 
statements, ultimately providing 62 statements for 
the Delphi process19. The experts were then allocated 
to groups of three and each member also functioned as 
lead expert for one statement, generating a short sum-
mary of the available evidence for this statement using 
the papers on the central server as a literature source, 
which was further updated as needed. The statements 
covered the following aspects: definition, pathophysiol-
ogy, diagnosis and treatment. Statements were revised 
by the chairs based on the feedback from the Consensus 
Group before the start of the first voting round and 
based on additional literature reviews, and also after 
each voting round.
Two voting rounds followed where each statement 
was presented with the evidence summary, and then 
the entire panel indicated the degree of agreement for the 
statement using a six- point Likert scale (Table 1). When 
at least 80% of the Consensus Group agreed (A+ or A) 
with a statement, this was defined as a consensus. All 
votes were fully anonymous, with no one knowing how 
anyone else voted.
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Definition and symptoms
1: Dumping syndrome is a frequent complication of 
oesophageal, gastric or bariatric surgery. 
•	 Statement endorsed.
•	Overall agreement 80%: A+ 65%, A 15%, A− 10%, 
D− 5%, D 0%, D+ 5%.
•	Grade B.
2: Dumping syndrome consists of a constellation of symp-
toms that can be categorized as early dumping syndrome 
or late dumping syndrome. 
•	 Statement endorsed.
•	Overall agreement 95%: A+ 90%, A 5%, A− 5%, 
D− 0%, D 0%, D+ 0%.
•	Grade B.
Dumping syndrome occurs in approximately 20% of 
patients who undergo vagotomy with pyloroplasty, in up 
to 40% of patients after gastrectomy and in up to 50% of 
patients who undergo oesophagectomy1,20. Dumping syn-
drome has also been reported after Nissen fundoplication 
in both children and adults13,20,21. Over the past decade, 
bariatric surgery has become the principal cause of post-
operative dumping syndrome. Furthermore, dumping 
syndrome has mainly been reported after RYGB and par-
tial gastrectomy7,20. Moreover, among 450 patients who 
had undergone RYGB or sleeve gastrectomy, approxi-
mately one- third (34.2%) had postoperative symptoms 
consistent with postprandial hypoglycaemia, indicating 
the presence of late dumping syndrome7,22.
Dumping syndrome consists of a constellation of 
symptoms that can be subdivided into early dumping 
syndrome or late dumping syndrome on the basis of the 
time at which the symptoms appear and the presumed 
underlying pathophysiology1,17,20. Early dumping syn-
drome is characterized by gastrointestinal symptoms 
such as abdominal pain, bloating, borborygmi, nausea 
and diarrhoea, and vasomotor symptoms such as fatigue, 
desire to lie down after meals, flushing, palpitations, per-
spiration, tachycardia, hypotension and, rarely, syncope. 
Symptoms of late dumping syndrome are related to neu-
roglycopenia (indicated by fatigue, weakness, confusion, 
hunger and syncope) and autonomic and/or adrenergic 
reactivity (indicated by perspiration, palpitations, tremor 
and irritability).
3: Early dumping syndrome symptoms occur within the 
first hour after a meal. 
•	 Statement endorsed.
•	Overall agreement 95%: A+ 80%, A 15%, A− 5%, 
D− 0%, D 0%, D+ 0%.
•	Grade B.
4: Early dumping syndrome is characterized by gastro-
intestinal symptoms (such as abdominal pain, cramps, 
bloating, borborygmi, nausea and diarrhoea) and vaso-
motor symptoms (such as fatigue, desire to lie down after 
meals, flushing, palpitations, perspiration, tachycardia, 
hypotension and, rarely, syncope). 
•	 Statement endorsed.
•	Overall agreement 100%: A+ 95%, A 5%, A− 0%, 
D− 0%, D 0%, D+ 0%.
•	Grade B.
5: Late dumping syndrome usually occurs 1–3 h after a 
meal and is characterized by (reactive) hypoglycaemia. 
•	 Statement endorsed.
•	Overall agreement 95%: A+ 85, A 10%, A− 5%, 
D− 0%, D 0%, D+ 0%.
•	Grade A.
Symptoms of early dumping syndrome are attributed 
to rapid passage of nutrients to the small intestine, which 
activates a cascade of pathophysiological events. The 
arrival of hyperosmolar contents in the small intestine 
triggers a shift of fluid from the intravascular component 
to the intestinal lumen, leading to decreased circulating 
blood volume, duodenal or jejunal distention and release 
of several gastrointestinal peptide hormones. These 
changes trigger symptoms of early dumping syndrome 
such as tachycardia, hypotension and, rarely, syncope as 
well as abdominal cramps. Provocative tests for assessing 
dumping syndrome (a modified oral glucose tolerance 
test (OGTT)) have shown that most of these symptoms, 
or their consequences (increased pulse rate and rise 
in the haematocrit level), are already present at 30 min 
after the meal1,17,20. Late dumping syndrome can be 
attributed to the development of hyperinsulinaemic, or 
reactive, hypoglycaemia. Rapid delivery of carbohydrates 
to the small intestine leads to high glucose concentra-
tions, which triggers a hyperinsulinaemic response, and 
Table 1 | GRADE system18
Code Quality of evidence Definition
A High Further research is very unlikely to change our confidence in the estimate of effect; 
the statement can be supported by several high- quality studies with consistent 
results or in special cases by one large, high- quality multicentre trial
B Moderate Further research is likely to have an important effect on our confidence in the 
estimate of effect and might change the estimate; the statement can be supported 
by one high- quality study or several studies with some limitations
C Low Further research is very likely to have an important effect on our confidence in 
the estimate of effect and is likely to change the estimate; the statement can be 
supported by one or more studies with severe limitations
D Very low Any estimate of effect is very uncertain; the statement can be supported by expert 
opinion or one or more studies with very severe limitations, or there might be no 
direct research evidence
Six- point Likert scale for assessment of agreement level: A+, agree strongly; A , agree with minor reservation; A−, agree with major 
reservation; D−, disagree with major reservation; D, disagree with minor reservation; D+, disagree strongly. GRADE, grading of 
recommendations assessment, development and evaluation.
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subsequent hypoglycaemia1,20. After bariatric surgery, it 
takes 3 months to 1 year for clinical signs of hypogly-
caemia to appear, perhaps because insulin sensitivity 
increases as weight loss occurs23.
6: Early dumping syndrome is the typical and most fre-
quent manifestation of dumping syndrome and might 
occur in isolation or in association with symptoms of 
late dumping syndrome. 
•	 Statement endorsed.
•	Overall agreement 90%: A+ 50%, A 40%, A− 5%, 
D− 5%, D 0%, D+ 0%.
•	Grade B.
The literature is not clear on the relative prevalence 
of early dumping syndrome versus late dumping syn-
drome. However, studies involving glucose tolerance 
testing show a very high occurrence of increased pulse 
rate, a marker of early dumping syndrome, and a lower 
occurrence of hypoglycaemia, a marker of late dump-
ing syndrome. These findings suggest that early dumping 
syndrome might be more prevalent than late dump-
ing syndrome1,17,20. Using the Mine score for symptom 
assessments, a higher proportion of patients reported 
early dumping syndrome than late dumping syndrome 
after gastric surgery for cancer24. By contrast, isolated 
late dumping syndrome (hypoglycaemia as the only 
symptom) might affect up to 25% of patients who have 
undergone surgery for gastric cancer5,7.
7: In severe cases, dumping syndrome is associated with 
a substantial reduction in quality of life. 
•	 Statement endorsed.
•	Overall agreement 95%: A+ 85%, A 10%, A− 5%, 
D− 0%, D 0%, D+ 0%.
•	Grade B.
Several studies in the 1990s reported the effect 
of dumping syndrome symptoms after gastrectomy 
on daily functioning25–27. More recent studies, using 
the Gastrointestinal Quality of Life Index (GIQLI), the 
Short- Form 36 or the RAND-36 questionnaire showed 
values well below the healthy population range17,27,28. 
A specific postgastrectomy quality of life instrument was 
developed, which documented considerably impaired 
quality of life after gastrectomy, with an important neg-
ative effect of dumping syndrome symptoms23. However, 
this scale uses the presence and number of symptoms 
of both early and late dumping syndrome and, hence, 
is driven by the physician rather than added to by the 
patient. Specific patient- administered quality of life 
scales for dumping syndrome are lacking.
8: In severe cases, dumping syndrome is associated with 
weight loss. 
•	 Statement endorsed.
•	Overall agreement 95%: A+ 65%, A 30%, A− 0%, 
D− 0%, D 5%, D+ 0%.
•	Grade B.
It is well established that bariatric surgery is associ-
ated with weight loss and a risk of dumping syndrome. 
However, literature from the peptic ulcer surgery era 
and data from gastric and oesophageal cancer surgery 
around the turn of the century also show that dump-
ing syndrome might lead to weight loss29,30. In addition, 
procedures that aim to prevent dumping syndrome such 
as vagus sparing oesophagectomy or pyloric reconstruc-
tion with gastric cancer surgery are associated with less 
weight loss than traditional resection procedures19,31–35. 
Weight loss was also reported in adults and children with 
dumping syndrome after Nissen fundoplication13,21,36.
Pathophysiology
9: In early dumping syndrome, probably due to hyper-
osmolality of the food, rapid fluid shifts occur from 
the plasma compartment to the intestinal lumen. The 
fluid shift accounts for part of the cardiovascular early 
dumping response. 
•	 Statement endorsed.
•	Overall agreement 85%: A+ 45%, A 40%, A− 5%, 
D− 5%, D 5%, D+ 0%.
•	Grade B.
10: Dumping syndrome might occur after gastric sur-
gery with removal of the barrier function of the pylorus, 
resulting in the rapid delivery of a substantial amount of 
undigested solid food to the small intestine. 
•	 Statement endorsed.
•	Overall agreement 100%: A+ 75%, A 25%, A− 0%, 
D− 0%, D 0%, D+ 0%.
•	Grade B.
11: Dumping syndrome might occur after gastric sur-
gery that reduces gastric volume capacity, resulting in 
the rapid delivery of a substantial amount of undigested 
solid food to the small intestine. 
•	 Statement endorsed.
•	Overall agreement 90%: A+ 70%, A 20%, A− 0%, 
D− 5%, D 5%, D+ 0%.
•	Grade B.
12: Movement of fluid into the small bowel related to 
dumping syndrome might cause distention and contrib-
ute to cramp- like contractions, bloating and diarrhoea. 
•	 Statement endorsed.
•	Overall agreement 90%: A+ 55%, A 35%, A− 10%, 
D− 0%, D 0%, D+ 0%.
•	Grade B.
13: In early dumping syndrome, release of several gastro-
intestinal hormones, including vasoactive agents, incre-
tins and glucose modulators, induces gastrointestinal 
symptoms and haemodynamic effects. 
•	 Statement endorsed.
•	Overall agreement 95%: A+ 60%, A 35%, A− 5%, 
D− 0%, D 0%, D+ 0%.
•	Grade B.
Gastric surgery can reduce gastric volume or remove 
the barrier function of the pylorus, which allows rapid 
delivery of food into the small intestine. Hyperosmolar 
small bowel content causes a shift of fluid from the vas-
cular compartment to the intestinal lumen, resulting in 
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a reduced circulating volume of plasma, tachycardia, 
hypotension and, rarely, syncope. Movement of fluid 
into the small bowel might also cause duodenal or jeju-
nal distension and generate abdominal symptoms such 
as cramping, diarrhoea, pain and bloating. The fluid 
shift is confirmed by the rise in haematocrit level at 
30 min during the glucose tolerance test that is seen in a 
subset of the patients studied1,17,20. A compensatory drop 
in atrial natriuretic peptide secretion occurs37. However, 
volume shifts are probably not the only mechanism as 
intravenous fluid substitution was found to be ineffective 
in preventing early dumping syndrome symptoms38. The 
role of gastric volume is illustrated by the occurrence of 
dumping syndrome after the sleeve gastrectomy bariatric 
procedure and also after a Nissen fundoplication5,6,13,21,36.
The second mechanism involved in the pathophysi-
ology of early dumping syndrome is probably enhanced 
release of several gastrointestinal hormones, including 
vasoactive agents (such as neurotensin and vasoactive 
intestinal peptide), incretins (such as glucagon- like pep-
tide 1 (GLP1)), YY gastric inhibitory polypeptide and glu-
cose modulators (such as insulin and glucagon)1,17,20,39–47. 
The levels of all gut peptides do not rise in dumping syn-
drome; for instance, levels of substance P and motilin 
did not increase42,43. In addition to chemosensing, duo-
denal or jejunal distention might also contribute to the 
release of these gastrointestinal hormones. Anecdotal 
evidence in support of this observation includes the 
frequent finding of a dilated small bowel during bar-
ium radiography in patients with dumping syndrome 
(interpreted in part as hypersecretion) and the induc-
tion of symptoms by duodenal distention in healthy vol-
unteers48–50. Through their actions, the released peptide 
hormones might contribute to both the gastrointestinal 
and the cardiovascular effects of dumping syndrome.
14: Rapid delivery of undigested carbohydrates to the 
small intestine might result in high concentrations of glu-
cose that induce a hyperinsulinaemic response, resulting 
in subsequent hypoglycaemia and related late dumping 
syndrome. 
•	 Statement endorsed.
•	Overall agreement 100%: A+ 80%, A 20%, A− 0%, 
D− 0%, D 0%, D+ 0%.
•	Grade A.
15: An exaggerated GLP1 response is the key mediator of 
the hyperinsulinaemic and hypoglycaemic effect that is 
characteristic of late dumping syndrome. 
•	 Statement endorsed.
•	Overall agreement 90%: A+ 50%, A 40%, A− 5%, 
D− 0%, D 0%, D+ 5%.
•	Grade B.
Enteral glucose administration induces enhanced 
insulin release relative to intravenous administration, 
which is the so- called incretin effect. Glucose- dependent 
insulinotropic polypeptide (also called gastric inhibitory 
polypeptide) and GLP1 have a pivotal role in the incretin 
effect. Patients with reactive hypoglycaemia after gastric 
surgery have an increased GLP1 response, and the rising 
levels of GLP1 are correlated with insulin release1,20,41,51–53. 
In addition, infusion of the GLP1 receptor antago-
nist exendin (9–39) amide was able to correct reactive 
hypoglycaemia after gastric bypass surgery52. These 
observations support an exaggerated GLP1 response as 
a key mediator of the hyperinsulinaemic and reactive 
hypoglycaemic effect in late dumping syndrome.
16: Dumping syndrome occurring after bariatric surgery 
can be associated with weight loss. 
•	 Statement endorsed.
•	Overall agreement 80%: A+ 60%, A 20%, A− 10%, 
D− 5%, D 5%, D+ 0%.
•	Grade B.
17: Dumping syndrome occurring after bariatric surgery 
can contribute to weight loss. 
•	 Statement endorsed.
•	Overall agreement 80%: A+ 60%, A 20%, A− 10%, 
D− 10%, D 0%, D+ 0%.
•	Grade B.
The success of RYGB surgery is usually attributed 
to gastric volume reduction and calorie malabsorption 
secondary to the bypass of the small intestine, which 
leads to markedly changed eating behaviour and meal 
patterns54,55. Other mechanisms that contribute to post-
operative weight loss include reduced hunger, increased 
satiation, increased energy expenditure and altered taste 
perception, all of which might be mediated by alterations 
in gastrointestinal and central neuroendocrine signal-
ling56–59. It has been proposed that dumping syndrome, 
through its adverse effects on food tolerance and intake, 
might be an essential component of the weight reduction 
after bariatric surgery55. However, no trial has demon-
strated that participants who have dumping syndrome 
symptoms lose more weight than those who do not have 
dumping syndrome, and this finding was confirmed in 
dedicated studies11,60. Hence, dumping syndrome occur-
ring after bariatric surgery is not a desired effect and must 
be considered a procedure complication as it can impair 
quality of life and digestive functions. Furthermore, to 
what extent a low frequency or mild intensity mani-
festation of dumping syndrome is a normal event after 
bariatric surgery also has not been established.
18: Reactive hypoglycaemia in patients who did 
not undergo upper gastrointestinal surgery can be a 
manifestation of idiopathic dumping syndrome. 
•	 Statement not endorsed.
•	Overall agreement 75%: A+ 20%, A 55%, A− 10%, 
D− 15%, D 0%, D+ 0%.
•	Grade C.
The literature has reported on small numbers of 
patients with reactive hypoglycaemia without prior sur-
gery who exhibit late hypoglycaemia in an oral glucose 
challenge test61. Rapid gastric emptying seemed to be 
the common underlying mechanism62. As a result of 
associated gastrointestinal symptoms, the rapid gastric 
emptying and the frequent association with postpran-
dial diarrhoea, reactive hypoglycaemia seems to be an 
underlying mechanism that is similar to that of dumping 
www.nature.com/nrendo
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syndrome after surgery. These patients responded well to 
dietary adjustment (frequent small meals)61.
Symptom- based diagnosis
19: Dumping syndrome should be suspected based on the 
concurrent presentation of multiple suggestive symptoms 
in patients who have undergone gastric or oesophageal 
surgery. 
•	 Statement endorsed.
•	Overall agreement 100%: A+ 70%, A 30%, A− 0%, 
D− 0%, D 0%, D+ 0%.
•	Grade B.
While this statement seems obvious, in clinical prac-
tice dumping syndrome is insufficiently known and is 
often missed. Furthermore, diagnosis and the appropri-
ate treatment are often delayed for several months or 
years. Profound fatigue after meal ingestion, with the 
need to lie down, in patients with an appropriate sur-
gical history is an important clinical clue1,20. In patients 
with suspected dumping syndrome, the diagnosis can 
be established using symptom- based questionnaires, 
by oral glucose challenge testing and other diagnostic 
investigations (see subsequent sections).
Mechanical obstruction or subobstruction (narrow-
ing of the lumen that slows but does not block passage 
of content) needs to be considered in the differential 
diagnosis of gastrointestinal symptoms in patients with a 
surgical history suggestive of dumping syndrome. How-
ever, mechanical alterations after surgery might mimic 
some of the early symptoms of dumping syndrome, 
but will not be associated with hypoglycaemia and will 
not result in any of the abnormal features during a glu-
cose tolerance test that are seen in patients with dump-
ing syndrome63,64. Clinical judgement will guide the 
extent to which additional testing is done to evaluate 
the postsurgical anatomy.
20: Symptom- based questionnaires, such as the Sigstad’s 
score and the Arts dumping questionnaire, can be used 
to identify patients with clinically meaningful dumping 
syndrome symptoms. 
•	 Statement not endorsed.
•	Overall agreement 70%: A+ 30%, A 40%, A− 15%, 
D− 10%, D 5%, D+ 0%.
•	Grade C.
21: Sigstad’s dumping score questionnaire is sensitive to 
therapy. 
•	 Statement not endorsed.
•	Overall agreement 30%: A+ 20%, A 10%, A− 35%, 
D− 15%, D 5%, D+ 15%.
•	Grade C.
22: The diagnostic accuracy of the Sigstad’s scoring 
questionnaire is similar in patients undergoing peptic 
ulcer surgery, bariatric surgery or upper gastrointestinal 
cancer surgery. 
•	 Statement not endorsed.
•	Overall agreement 20%: A+ 20%, A 20%, A− 20%, 
D− 20%, D 10%, D+ 10%.
•	Grade C.
23: The diagnostic accuracy of the Sigstad’s scoring ques-
tionnaire is acceptable for identifying early dumping 
syndrome after peptic ulcer surgery only. 
•	 Statement not endorsed.
•	Overall agreement 45%: A+ 0%, A 45%, A− 10%, 
D− 25%, D 15%, D+ 5%.
•	Grade C.
24: Arts dumping- severity score questionnaire is able 
to discriminate patients with early and late dumping 
syndrome. 
•	 Statement not endorsed.
•	Overall agreement 75%: A+ 50%, A 25%, A− 10%, 
D− 10%, D 5%, D+ 0%.
•	Grade B.
25: Arts dumping- severity score questionnaire is sensitive 
to therapeutic effects. 
•	 Statement not endorsed.
•	Overall agreement 65%: A+ 25%, A 40%, A− 15%, 
D− 15%, D 5%, D+ 0%.
•	Grade B.
26: The Dumping Symptom Rating Scale patient self- 
assessment questionnaire is accurate in determining 
symptom severity and frequency in dumping syndrome 
both preoperatively and postoperatively (for example, 
RYGB). 
•	 Statement not endorsed.
•	Overall agreement 45%: A+ 20%, A 25%, A− 30%, 
D− 15%, D 10%, D+ 0%.
•	Grade C.
The Sigstad’s scoring system, which was proposed in 
1970, is designed to aid the diagnosis of dumping syn-
drome by allocating points to symptoms, which are then 
added up3 (box 1). The total points are summarized into 
a calculated diagnostic index; if the score is above 7 it 
is suggestive of dumping syndrome and if the score is 
<4 then other diagnoses need to be considered65. Scores 
of 5 and 6 represent a grey area as what they mean for 
the diagnosis of dumping syndrome is unclear. However, 
these values and their interpretation were established for 
patients undergoing peptic ulcer surgery and the diag-
nostic accuracy of the Sigstad’s scoring questionnaire 
in patients undergoing bariatric surgery or upper gas-
trointestinal cancer surgery has not been established. 
A study of 50 patients who underwent gastric bypass 
found a Sigstad’s score indicative of dumping syn-
drome in 42% of the patients, without correlation to the 
amount of weight loss11. However, a study in 24 patients 
without type 2 diabetes mellitus who were undergoing 
laparoscopic sleeve gastrectomy showed a disconnect 
between the score and hypoglycaemia during the glucose 
challenge test11.
The Sigstad’s scoring system was mainly proposed 
as a diagnostic aid. To our knowledge, its sensitivity to 
treatment interventions has not been studied. Laurenius 
and colleagues reported a modified use of the Sigstad’s 
score, at 15-min intervals during an OGTT, and the area 
under the curve distinguished patients with or without 
symptoms of dumping syndrome after RYGB66. Whether 
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this method was superior to the classic score was not 
reported; in addition, no diagnostic cut- offs were iden-
tified. Taking these findings together, the Sigstad’s score 
correctly identifies a substantial group of patients with 
dumping syndrome after all types of surgeries; however, 
there are insufficient data to compare the diagnostic effi-
cacy of Sigstad’s scoring system after bariatric surgery 
versus cancer or peptic ulcer surgery.
In the dumping severity score developed by Arts 
and colleagues, symptoms of early and late dumping 
syndrome (which have eight and six symptoms, respec-
tively) are scored on a four- point Likert scale17 (box 2). 
Severity scores are obtained by adding the individ-
ual scores of the symptoms displayed by the patient. 
This score was mainly used as an index of severity. The 
diagnostic performance has not been addressed. In 
addition, no threshold was established for any of the 
subscores (late or early). Hence, although this score 
quantifies symptoms, its discriminatory value for early 
versus late dumping syndrome has not been addressed.
In open- label studies of the somatostatin analogues 
octreotide and lanreotide, early, late and total Arts scores 
were altered following treatment17,67. By contrast, no 
statistically significant improvement in Arts scores 
was found in a pilot study with the somatostatin ana-
logue pasireotide68; however, the authors argued that 
the applied dose might have been too high, inducing 
gastrointestinal adverse effects.
A report published in 2010 describes the use of a 
visual analogue scale (severity of symptoms indicated 
on a 10-cm line with severity ranging left to right from 
0 to intolerable) survey to evaluate seven symptoms 
of early dumping syndrome and six symptoms of late 
dumping syndrome in more than 1,000 patients who had 
undergone gastrectomy for gastric cancer24. The analy-
sis generated a very low cut- off for diagnosing dump-
ing syndrome (visual analogue scale score >10 mm on 
a single item on the questionnaire), but surprisingly a 
higher cut- off (45 mm) gave similar diagnostic yield24. 
No other reports on the use of this questionnaire are 
available to date.
The Dumping Symptom Rating Scale is a question-
naire based on input from a multidisciplinary team of 
physicians8. This scale comprises nine symptoms address-
ing early dumping syndrome, one on symptoms related 
to drinking fluids and one related to consuming sweet-
ened drinks. A summary score is generated by multi-
plying individual scores for severity (range 1–9) and 
frequency (range 1–8) for each item and adding these 
up. Content validity, internal consistency and construct 
validity were established in a large patient cohort. Test–
retest reliability was less consistent. Variable correla-
tions were found with items from the Gastrointestinal 
Symptom Rating Scale. Furthermore, responsiveness to 
therapy has not been assessed for this scale.
Diagnostic testing
27: Spontaneous plasma levels of glucose <2.8 mmol/l 
(50 mg/dl) are indicative of late dumping syndrome. 
•	 Statement endorsed.
•	Overall agreement 80%: A+ 50%, A 30%, A− 0%, 
D− 5%, D 15%, D+ 0%.
•	Grade B.
28: Spontaneous plasma levels of glucose <3.3 mmol/l 
(60 mg/dl) are indicative of late dumping syndrome. 
•	 Statement not endorsed.
•	Overall agreement 45%: A+ 30%, A 15%, A− 30%, 
D− 10%, D 10%, D+ 5%.
•	Grade C.
Hypoglycaemia is relevant when it is accompanied 
by symptoms that are relieved by ingestion of carbo-
hydrates. This is referred to as Whipple’s triad in the 
literature on insulinoma and postbariatric surgery hypo-
glycaemia69,70. Although no definitive cut- off values were 
defined for random glucose concentrations in a literature 
review published in 2015, the use of glucose concentra-
tions below 3.3 mmol/l has been suggested as a sensitive 
cut- off value for meal- induced hypoglycaemia during 
OGTT or a mixed meal tolerance test71. This cut- off 
value has also been used by other authors in paediatric 
patients72 as well as in adult patients73. This cut- off value 
is used after a glucose load, with the patient sitting in a 
chair over a long period of time for repeated blood sam-
ples and hence using very little energy. In that respect 
it seems acceptable to require a stricter cut- off, such 
as 2.8 mmol/l rather than 3.3 mmol/l, for spontaneous 
events. In a study using continuous glucose monitoring 
on reactive hypoglycaemia, the cut- off for hypoglycae-
mia events was 70 mg/dl (3.9 mmol/l)74. In another study 
measuring continuous glycaemia in patients with reac-
tive hypoglycaemia, a cut- off of 3.3 mmol/l (60 mg/dl) 
was used, but only 5% of symptom episodes were below 
this threshold75. In a study with acarbose, a threshold of 
60 mg/dl was also used to assess hypoglycaemia76.
Data from the literature on diabetes mellitus treated 
with insulin show an increase in the occurrence of 
symptomatic hypoglycaemia from levels of 3.9 mmol/l 
Box 1 | Dumping syndrome symptoms according to the Sigstad’s scoring system
the sigstad’s scoring system was developed in the era of peptic ulcer surgery and 
assigns points to each of 16 symptoms of dumping syndrome, and the total points are 
used to calculate a diagnostic index. A diagnostic index >7 is suggestive of dumping 
syndrome, whereas a score <4 suggests that other diagnoses should be considered.
•	shock +5
•	Fainting (syncope), unconsciousness +4
•	Desire to lie or sit down +4
•	Breathlessness (dyspnoea) +3
•	Weakness, exhaustion +3





•	Feeling of warmth, sweating, pallor, clammy skin +1
•	Nausea +1
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and below. From an extensive database analysis, the 
majority of hypoglycaemia episodes above 3.5 mmol/l 
remained asymptomatic, and it was concluded that val-
ues between 3.5 mmol/l and 4.0 mmol/l are probably 
of minor importance, and that a cut- off of 3.4 mmol/l 
(54 mg/dl) is appropriate in the setting of patients with 
diabetes mellitus treated with insulin77. Ambulatory 
glycaemia monitoring studies used lower cut- off levels 
for hypoglycaemia (3.1 mmol/l and even 2.2 mmol/l), 
but no consensus is currently reached on thresholds78. 
The 2.2 mmol/l threshold was proposed as this level of 
hypoglycaemia leads to notable and sustained cogni-
tive impairment (from the UK Hypoglycaemia Study 
Group)79.
In summary, no consensus on the glucose concen-
tration that defines hypoglycaemia is available from 
the literature (either literature on dumping syndrome 
or the broader literature). A cut- off of 3.3 mmol/l seems 
reasonable, but 2.8 mmol/l is more predictably associ-
ated with symptoms, and was supported by the current 
Delphi consensus.
29: Continuous glucose monitoring is beneficial in 
dumping syndrome. 
•	 Statement not endorsed.
•	Overall agreement 65%: A+ 35%, A 30%, A− 15%, 
D− 5%, D 15%, D+ 0%.
•	Grade C.
30: Continuous glucose monitoring is beneficial for 
identifying complex cases of dumping syndrome. 
•	 Statement not endorsed.
•	Overall agreement 70%: A+ 50%, A 20%, A− 10%, 
D− 15%, D 5%, D+ 0%.
•	Grade C.
31: Continuous glucose monitoring is a reproducible 
assay in identifying dumping syndrome. 
•	 Statement not endorsed.
•	Overall agreement 35%: A+ 10%, A 25%, A− 35%, 
D− 5%, D 15%, D+ 10%.
•	Grade C.
Anecdotal reports suggest that monitoring glycae-
mia is useful in patients with suspected dumping syn-
drome80–84. One case report and one therapeutic study 
used continuous glucose monitoring as an outcome vari-
able to assess the effect of acarbose and dietary mea-
sures75,82. However, the diagnostic accuracy of continuous 
glucose monitoring has not been compared with that of 
dumping provocative tests or diagnostic questionnaires 
or been evaluated as a marker of therapeutic outcome.
32: Sigstad’s scoring system can identify early dumping 
syndrome by diagnosing signs and symptoms such as a 
high pulse rate or increased haematocrit level that are 
indicative of hypovolaemia during an OGTT. 
•	 Statement not endorsed.
•	Overall agreement 60%: A+ 25%, A 35%, A− 15%, 
D− 10%, D 10%, D+ 5%.
•	Grade B.
In its original report, the Sigstad’s diagnostic question-
naire test was proposed to be combined with an OGTT in 
the diagnostic work- up and the Sigstad’s scoring system; 
the scores and outcomes of the provocative test differed in 
25 patients with or without dumping syndrome after gas-
trectomy64. The Sigstad’s scoring system primarily aims 
to identify early dumping syndrome through signs and 
symptoms such as a high pulse rate or increased haemat-
ocrit level that are indicative of hypovolaemia. The index 
does not use hypoglycaemia (a marker of late dump-
ing syndrome) and hence it is likely to underestimate 
prevalence and severity of dumping syndrome.
33: In the modified glucose tolerance test, patients with 
suspected dumping syndrome ingest 75 g of glucose in 
solution after an overnight fast; blood concentrations 
of glucose, haematocrit level, pulse rate and blood pres-
sure are measured before and at 30- min intervals up to 
180 min after ingestion. 
•	 Statement endorsed.
•	Overall agreement 95%: A+ 60%, A 35%, A− 0%, 
D− 0%, D 5%, D+ 0%.
•	Grade B.
34: The modified OGTT is considered positive for 
early dum ping syndrome based on the presence of 
an early (30 min) increase in haematocrit level >3% or an 
increase in pulse rate >10 bpm 30 min after ingestion. 
•	 Statement endorsed.
•	Overall agreement 90%: A+ 70%, A 20%, A− 0%, 
D− 10%, D 0%, D+ 0%.
•	Grade B.
Box 2 | Dumping syndrome symptoms according to the Arts scoring system
In the Arts scoring system, a distinction is made between eight symptoms of early 
dumping syndrome (first hour after the meal) and six symptoms of late dumping 
syndrome (occurring after the first hour). each symptom is scored for severity on a 0–3 
likert scale (absent to severe). early and late dumping syndrome scores are calculated 
as, respectively, the sum of the eight symptoms of early dumping syndrome and the six 
symptoms of late dumping syndrome. the total severity score for dumping syndrome is 
the sum of severities of all symptoms.

















For each symptom: 0 = absent, 1 = mild, 2 = relevant and 3 = severe
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35: The modified OGTT is considered positive for late 
dumping syndrome based on the development of late 
(60–180 min after ingestion) hypoglycaemia (<50 mg/dl). 
•	 Statement endorsed.
•	Overall agreement 80%: A+ 40%, A 40%, A− 15%, 
D− 5%, D 0%, D+ 0%.
•	Grade B.
36: The modified OGTT is considered positive for late 
dumping syndrome based on the development of late 
(60–180 min after ingestion) hypoglycaemia (<60 mg/dl). 
•	 Statement not endorsed.
•	Overall agreement 60%: A+ 40%, A 20%, A− 20%, 
D− 10%, D 5%, D+ 5%.
•	Grade B.
37: The modified OGTT is an assay for identifying 
dumping syndrome that has good reproducibility. 
•	 Statement not endorsed.
•	Overall agreement 35%: A+ 10%, A 25%, A− 35%, 
D− 15%, D 15%, D+ 0%.
•	Grade C.
38: The modified OGTT has a good specificity but a low 
sensitivity for dumping syndrome. 
•	 Statement not endorsed.
•	Overall agreement 45%: A+ 10%, A 35%, A− 55%, 
D− 0%, D 0%, D+ 0%.
•	Grade B.
39: To increase the low sensitivity of the modified OGTT, 
especially in patients after gastric bypass surgery, a 
validated questionnaire should be added to the test. 
•	 Statement not endorsed.
•	Overall agreement 55%: A+ 20%, A 35%, A− 30%, 
D− 0%, D 15%, D+ 0%.
•	Grade B.
40: The mixed meal tolerance test is more sensitive 
than the modified OGTT for diagnosing late dumping 
syndrome. 
•	 Statement not endorsed.
•	Overall agreement 35%: A+ 10%, A 25%, A− 35%, 
D− 10%, D 15%, D+ 5%.
•	Grade C.
The OGTT is now the preferred diagnostic test for 
dumping syndrome1,20,85. This test generally involves the 
ingestion of 50 g or 75 g glucose in solution, but glucose 
doses between 25 g and 100 g have been used by various 
authors69. Blood concentration of glucose, haematocrit 
level, pulse rate and blood pressure are measured at 
30- min intervals for up to 3 h after the ingestion.
The test is considered positive if late (120–180 min) 
hypoglycaemia occurs, or if an early (30 min) increase 
in haematocrit level of more than 3% occurs. The most 
sensitive sign of early dumping syndrome seems to 
be a rise in the pulse rate by more than 10 bpm after 
30 min1,17,20,67,68,85,86. Most studies have considered gly-
caemia below 60 mg/dl, usually occurring between 
90 min and 180 min after ingestion, as diagnostic 
of late dumping syndrome. Hypoglycaemia is a marker 
of late dumping syndrome and hence, if present, allows 
a diagnosis of dumping syndrome. Its absence does 
not exclude a diagnosis of dumping syndrome as early 
dumping syndrome might be present in the absence 
of late dumping syndrome1. In the literature from the 
past few years, this level of glycaemia mostly occurred 
at 120 min, 150 min or 180 min1,17,67,68,85,86. No system-
atic analysis has compared cut- offs of 50 mg/dl versus 
60 mg/dl. However, based on our experience and sup-
ported by the available literature1,17,67,68,85,86, a cut- off of 
50 mg/dl during an OGTT, during which no physical 
activity is performed, might underestimate the preva-
lence of late dumping syndrome and decrease diagnostic 
sensitivity. Nevertheless, the current consensus selected 
50 mg/dl as a cut- off value for defining late hypogly-
caemia in dumping syndrome. OGTTs have also been 
used for long- term follow- up studies6. The clinical unit 
where the test is performed should be familiar with 
symptom atic hypoglycaemia during the OGTT and how 
to manage it. However, the literature does not report 
problematic adverse effects during repeated OGTT in 
patients with dumping syndrome17,66–68,85,86.
The reproducibility of the modified OGTT has not 
been studied separately. However, data from a phase II 
clinical trial involving pasireotide in patients with dump-
ing syndrome, where progressively increasing doses of 
pasireotide were added with repeated OGTT testing, 
show that up to 50% of patients continued to display 
hypoglycaemia during treatment86. This observation 
supports the concept that the test might be reproducible 
for the occurrence of hypoglycaemia. In these studies, at 
OGTT testing, the persistence of a rise in pulse rate or 
a rise in haematocrit level at 30 min with treatment was 
lower than the persistence of hypoglycaemia, suggest-
ing that either this aspect is less reproducible, or that 
pasireotide is more effective in treating early dumping 
syndrome (pulse rate rise and haematocrit rise) than in 
treating late dumping syndrome (hypoglycaemia).
The OGTT might demonstrate hypoglycaemia after 
gastric bypass surgery even in the absence of symptoms 
suggestive of late dumping syndrome69. The diagnostic 
accuracy of this test is therefore likely to be low. When 
patients without diabetes mellitus were tested before 
and after a bariatric procedure, predominantly gastric 
bypass, half of all patients developed hypoglycaemia; 
however, none had hypoglycaemic symptoms, which 
suggests the test has low specificity87. For this reason, 
it has been suggested that measured hypoglycaemia in 
patients after bariatric surgery is only relevant when 
associated with symptoms that are relieved by inges-
tion of carbohydrates (Whipple’s triad)69. On the basis 
of these considerations, the guideline for evaluation 
and management of adult hypoglycaemic disorders 
from the Endocrine Society that was published in 2009 
rejected the use of the OGTT for testing postprandial 
hypoglycaemia, but this guideline did not mention or 
consider dumping syndrome88. Whether the accuracy 
or sensitivity of the OGTT for dumping syndrome can 
be improved by adding questionnaires (such as Sigstad’s, 
Arts or Mine questionnaires) has not been evaluated.
As an alternative, the mixed meal tolerance test 
has been recommended to confirm the diagnosis of 
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symptomatic hypoglycaemia after gastric bypass69. In 
this test, patients with suspected dumping syndrome 
ingest a mixed meal containing carbohydrates, fat and 
proteins after an overnight fast, and blood samples are 
collected prior to the meal and at 30- min intervals for 
up to 2 h afterwards to measure glycaemic and insulin 
profiles. Compared to the OGTT, only a limited number 
of studies have reported on the mixed meal test53,89. No 
head- to- head comparisons are available, and hence eval-
uating respective sensitivities for the tests cannot be done 
reliably. However, this test was claimed to have a lower 
rate of hypoglycaemia occurrence than OGTT53,71,89.
41: A gastric emptying test showing rapid emptying rate 
can be used to confirm a diagnosis of dumping syndrome. 
•	 Statement not endorsed.
•	Overall agreement 30%: A+ 10%, A 20%, A− 30%, 
D− 15%, D 20%, D+ 5%.
•	Grade B.
42: Gastric emptying tests have low sensitivity and 
specificity for dumping syndrome. 
•	 Statement endorsed.
•	Overall agreement 85%: A+ 35%, A 50%, A− 5%, 
D− 5%, D 5%, D+ 0%.
•	Grade B.
Although rapid gastric emptying is a key mechanism 
in dumping syndrome, the diagnostic accuracy of rapid 
gastric emptying seems to be low. First, the test is not 
applicable after total gastrectomy. Second, rapid gastric 
emptying might occur in conditions other than dump-
ing syndrome — for instance, functional dyspepsia90,91. 
Furthermore, initial rapid gastric emptying is enough 
to trigger symptoms of dumping syndrome, but these 
symptoms, including nausea, might in turn delay gastric 
emptying, such that the overall value of gastric emptying 
rate is within the normal range, as has been reported in 
a number of series18,68. On the basis of these limitations, 
gastric emptying testing seems to be of low utility in 
diagnosing dumping syndrome.
Treatment
43: Dietary modification is the initial approach, and is 
usually beneficial for the majority of patients. 
•	 Statement endorsed.
•	Overall agreement 100%: A+ 80%, A 20%, A− 0%, 
D− 0%, D 0%, D+ 0%.
•	Grade B.
44: Clinicians should advise patients with dumping syn-
drome to reduce the amount of food consumed at each 
meal; moreover, patients should delay fluid intake until 
at least 30 min after meals. 
•	 Statement endorsed.
•	Overall agreement 90%: A+ 55%, A 35%, A− 10%, 
D− 0%, D 0%, D+ 0%.
•	Grade B.
45: Rapidly absorbable carbohydrates should be elimi-
nated from the diet to prevent symptoms of late dumping 
syndrome, such as hypoglycaemia. 
•	 Statement endorsed.
•	Overall agreement 90%: A+ 80%, A 10%, A− 10%, 
D− 0%, D 0%, D+ 0%.
•	Grade B.
46: Patients with dumping syndrome should be advised 
to eat a diet consisting of foods high in fibre and rich in 
protein, eaten slowly and chewed well. 
•	 Statement endorsed.
•	Overall agreement 80%: A+ 55%, A 25%, A− 15%, 
D− 5%, D 0%, D+ 0%.
•	Grade C.
47: Patients with dumping syndrome should be advised 
to lie down for 30 min after meals to reduce the symptoms 
of hypovolaemia. 
•	 Statement not endorsed.
•	Overall agreement 55%: A+ 35%, A 20%, A− 25%, 
D− 10%, D 5%, D+ 5%.
•	Grade C.
Dietary modification is the initial treatment approach 
where patients are advised to reduce the amount of 
food ingested at each meal, to postpone fluid intake 
until at least 30 min after meals and to eliminate rap-
idly absorbable carbohydrates, which are present in all 
sweet foods and drinks, for instance. Instead, patients 
are advised to eat a diet consisting of foods that are high 
in fibre and rich in protein; consumption of fruit and 
vegetables is encouraged, whereas alcoholic beverages 
are better avoided1. Case series in adults and children 
argue in favour of the benefit of dietary intervention, but 
the focus of these studies is on late dumping syndrome 
(hypoglycaemia)1,20,92–96. Patients should also eat slowly 
and chew well1. Controlled data showing benefit from 
protein- rich foods or delaying fluid intake are not avail-
able in the literature. Education about the glycaemic index 
of different foods might also be helpful for patients with 
dumping syndrome. In addition, patients can be advised 
to lie down for 30 min after meals to delay gastric empty-
ing and reduce the symptoms of hypovolaemia; however, 
evidence for this approach is lacking8,96–99.
48: Dietary supplements that increase the viscosity of 
food (such as guar gum, pectin and glucomannan) are a 
good second- line (after diet) treatment for symptoms of 
dumping syndrome. 
•	 Statement not endorsed.
•	Overall agreement 40%: A+ 20%, A 20%, A− 45%, 
D− 5%, D 10%, D+ 0%.
•	Grade B.
A number of studies have evaluated the use of sup-
plements that increase food viscosity, such as guar gum, 
pectin and glucomannan, in patients with dumping 
syndrome45,100–106 (Table 2). The rationale is that the 
increased consistency of the meal will slow the release of 
nutrients to the small intestine. Several studies evaluated 
the ingestion of up to 15 g of guar gum or pectin with 
each meal to slow gastric emptying, reduce the release 
of gastrointestinal hormones, improve hyperglycaemia 
and control symptoms of dumping syndrome45,100–106. 
NAtuRe RevIeWs | EnDoCRinoloGy
e v i d e n c e - B a s e d  g u i d e l i n e s
  volume 16 | August 2020 | 457
One study reported that glucomannan statistically sig-
nificantly improved glucose tolerance but had no effect 
on glucose absorption in children with dumping syn-
drome104. However, the palatability and tolerability of 
such dietary supplements are usually poor1.
49: Pharmacological intervention has to be considered in 
the management of dumping syndrome in patients who 
do not respond to dietary modification. 
•	 Statement endorsed.
•	Overall agreement 90%: A+ 80%, A 10%, A− 10%, 
D− 0%, D 0%, D+ 0%.
•	Grade B.
50: Acarbose can be used as a treatment for symptoms of 
late dumping syndrome. 
•	 Statement endorsed.
•	Overall agreement 85%: A+ 55%, A 30%, A− 10%, 
D− 5%, D 0%, D+ 0%.
•	Grade B.
51: Acarbose does not affect symptoms of early dumping 
syndrome. 
•	 Statement not endorsed.
•	Overall agreement 75%: A+ 35%, A 40%, A− 0%, 
D− 15%, D 5%, D+ 5%.
•	Grade B.
In patients with dumping syndrome who are not 
responding to dietary interventions the use of phar-
macological therapy needs to be considered because 
the efficacy of pharmacotherapy might be higher than 
dietary interventions and is better supported by mech-
anistic and controlled trials; furthermore, the effect of 
dumping syndrome on quality of life is considerable. 
Nevertheless, a conservative approach can be considered 
in patients who prefer not to progress to pharmacolog-
ical therapy, provided that no major symptoms, such as 
hypoglycaemia leading to diminished awareness, coma 
or inability to drive or function, are present.
Acarbose is an alpha- glycosidase inhibitor that slows 
the release of monoglycerides from nutritional carbo-
hydrates. The available studies with acarbose are sum-
marized in Table 3. Most studies are fairly small and of 
short duration. They consistently show that acarbose 
improves glucose tolerance, reduces gastrointestinal 
hormone release and reduces the incidence of hypo-
glycaemia, which is the main feature of late dumping 
syndrome12,76,107–116. No specific evidence of an effect 
on symptoms of early dumping syndrome is avail-
able. However, the absence of a detailed distinction of 
symptoms of early and late dumping syndrome in a few 
studies means that it cannot definitely be excluded that 
acarbose can also have an effect on treating symptoms 
of early dumping syndrome. The usual dose of acarbose 
is 50–100 mg three times a day with meals. The main 
adverse effect is flatulence and related gastrointestinal 
symptoms such as bloating due to carbohydrate mal-
absorption. For adherence reasons, patients should be 
informed about this effect as an inevitable adverse effect 
due to the mechanism of action of the drug.
52: Diazoxide, a potassium channel activator that inhib-
its calcium- induced insulin release, can be used as a 
treatment for symptoms of late dumping syndrome. 
•	 Statement not endorsed.
•	Overall agreement 50%: A+ 25%, A 25%, A− 25%, 
D− 15%, D 10%, D+ 0%.
•	Grade C.
Diazoxide inhibits insulin secretion by opening 
ATP- sensitive potassium channels in pancreatic β- cells, 
Table 2 | Summary of studies evaluating pectin, guar gum and glucomannan in dumping syndrome
Study n Treatment Result
Jenkins et al.104 9 Pectin 14.5 g, single administration 
prior to OGTT
Improved symptoms and glycaemia levels 
(normalized in 46%) during OGTT
Jenkins et al.105 11 Pectin 14.5 g, single administration 
prior to OGTT
Improved postprandial levels of glucose, insulin 
and enteroglucagon; reduced hypoglycaemia
Leeds et al.153 11 Pectin 15 g, single administration 
prior to OGTT
Improved vasomotor symptoms and glycaemia 
levels, lower insulin levels and slower gastric 
emptying during OGTT
Lawaetz et al.44 4 Pectin 15 g, single administration 
prior to OGTT
Reduced vasomotor symptoms, lower levels 
of insulin, glucagon, neurotensin and gastric 
inhibitory polypeptide, and slower initial 
gastric emptying during OGTT
Andersen et al.100 5 Pectin 5 g, single administration 
prior to muffin meal
No effect on symptoms or gastric emptying 
rate
Harju and Larmi101 11 Guar gum 5 g with meals Improvement of symptoms
Harju et al.102 11 Guar gum 5 g with meals Slowing of gastric emptying
Harju and Makela103 11 Guar gum 5 g with a glucose 
challenge meal
Improvement of symptoms and 
hyperglycaemia after a glucose challenge meal
Kneepkens et al.106 8 children Glucomannan 1.3 g, single 
administration prior to OGTT
Improvement of glucose tolerance, no effect 
on glucose absorption; however, no consistent 
effect on symptoms was seen
OGTT, modified oral glucose tolerance test.
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and is therefore expected to prevent the hypoglycaemia 
of late dumping syndrome. The use of diazoxide for 
symptoms of late dumping syndrome is only mentioned 
anecdotally in the literature, as case reports and case 
series117–120. Published in 2016, a multicentre, retrospec-
tive, systematic case series of six patients with hyperinsu-
linaemic hypoglycaemia after bariatric surgery reported 
that diazoxide reduced the number and severity of hypo-
glycaemic events in three patients119. In a small prospec-
tive case series, published as an abstract only, diazoxide 
significantly improved late hypoglycaemia without having 
any statistically significant effects on other parameters120.
53: Somatostatin analogues are the preferred treatment 
option for patients with well-established dumping syn-
drome who do not respond to initial dietary modification 
with or without acarbose treatment. 
•	 Statement endorsed.
•	Overall agreement 90%: A+ 65%, A 25%, A− 5%, 
D− 0%, D 5%, D+ 0%.
•	Grade B.
54: Both short- acting and long- acting formulations 
of somatostatin analogues are efficacious for treating 
symptoms of both early and late dumping syndrome. 
•	 Statement not endorsed.
•	Overall agreement 75%: A+ 40%, A 35%, A− 15%, 
D− 5%, D 5%, D+ 0%.
•	Grade B.
55: Short- acting somatostatin analogue formulations are 
more effective than long-acting formulations at improving 
symptoms of dumping syndrome. 
•	 Statement endorsed.
•	Overall agreement 80%: A+ 55%, A 25%, A− 20%, 
D− 0%, D 0%, D+ 0%.
•	Grade B.
56: The need for repeated injections of somatostatin ana-
logues throughout the day is a major limitation to the 
long- term administration of short- acting formulations. 
•	 Statement endorsed.
•	Overall agreement 90%: A+ 60%, A 30%, A− 10%, 
D− 0%, D 0%, D+ 0%.
•	Grade B.
Somatostatin analogues are able to slow the rate of 
gastric emptying, slow small bowel transit, inhibit the 
release of gastrointestinal hormones, inhibit insulin secre-
tion and inhibit postprandial vasodilation; these ana-
logues are therefore of potential benefit for both early and 
late dumping syndromes. The efficacy of somatostatin 
analogues for dumping syndrome was initially supported 
by case series120–128 and subsequently by several rand-
omized controlled trials2,28,67,129,130 (Table 4). The evidence 
applies to symptoms of both early and late dumping syn-
dromes, after peptic ulcer, bariatric and cancer surgeries. 
Studies from the Netherlands and Belgium have shown 
that both short- acting and long- acting somatostatin ana-
logues provide symptomatic benefit, but patients prefer 
the long- acting preparations, probably because of the 
lower number of injections nee ded17,28,67,121,126. Data from 
glucose challenge tests and the assessment of haema-
tocrit level and/or pulse rate provide objective evidence 
of the efficacy of octreotide and pasireotide in both early 
and late dumping syndrome17,68. Penning and colleagues 
Table 3 | Summary of studies evaluating acarbose in dumping syndrome
Study n Treatment Result
McLoughlin et al.111 10 Acarbose 100 mg single administration prior 
to OGTT
Improved symptoms and hyperglycaemia and hypoglycaemia during 
OGTT; reduced rise in plasma levels of gastric inhibitory polypeptide and 
insulin; no change in gastric emptying rate
Gerard et al.108 24 Acarbose 100 mg single administration prior 
to OGTT
Improved hyperglycaemia and hypoglycaemia during OGTT; reduced 
rise in plasma levels of insulin; inhibition of glucose- induced suppression 
of glucagon
Lyons et al.110 13 Acarbose 50 mg single administration prior 
to standard breakfast
Significant attenuation of hyperglycaemia; reduced rise in plasma 
levels of gastric inhibitory polypeptide, enteroglucagon and insulin; 
no influence on plasma levels of vasoactive intestinal polypeptide and 
somatostatin; no significant effect on symptoms
Hasegawa et al.109 6 Acarbose 50–100 mg 3 times per day before 
meals for a month
Attenuation of glucose fluctuations and improvement of dumping 
syndrome symptoms (uncontrolled)
Ozgen et al.113 21 Acarbose 150 mg per day before meals  
for 2 weeks and 300 mg per day for the 
remainder of the 3- month treatment period
Reduced early hyperglycaemic and hyperinsulinaemic response; 
reduced reactive hypoglycaemia
Ng et al.12 6 Acarbose 12.5 mg before a meal Improved postprandial hypoglycaemia
De Cunto et al.115 4 Acarbose 25–100 mg before meals Stabilized postprandial levels of glucose
Valderas et al.114 8 Acarbose 100 mg before a meal Avoided postprandial hypoglycaemia; reduced hyperinsulinaemic 
response; reduced GLP1 secretion
Ritz et al.76 8 Acarbose 50–100 mg, 3 times per day for  
6 weeks
Eliminated dumping syndrome symptoms and improved CGM profile
Speth et al.107 9 Acarbose 50–100 mg, pectin 4.2 g, acarbose 
50 mg plus pectin 4.2 g, placebo, after 
standard breakfast
Acarbose and acarbose plus pectin inhibited postprandial 
hyperglycaemia and hypoglycaemia; acarbose plus pectin inhibited 
hyperinsulinaemia; acarbose, pectin and combination therapy reduced 
hypoglycaemic symptoms
CGM, continuous glucose monitoring; GLP1, glucagon- like peptide 1; OGTT, modified oral glucose tolerance test.
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have shown how long- acting formulations are more 
effective than short- acting formulations in increasing 
body weight and improving quality of life28. However, in 
a study by Arts and colleagues, better symptom control 
was obtained with short- acting octreotide three times 
a day than with long- acting octreotide administered 
monthly17,28.
Indeed, long- acting octreotide (intramuscularly) 
might offer the potential advantage of less frequent 
injections that are more convenient for the patient 
and might reduce injection aversion, which was often 
reported with short- acting octreotide injections (subcu-
taneously)1,17. Octreotide use might be associated with 
the occurrence of hypoglycaemia as an adverse effect. 
Hence, in theory, a worsening or different pattern of 
hypoglycaemia with octreotide is possible. However, 
this effect has not been reported in any of the octreotide 
studies for dumping syndrome to date, which suggests 
this is not a relevant issue in this population17,28,67,68,121–131. 
Paediatric usage of octreotide or other analogues is not 
yet supported by solid evidence as no specific studies 
on dumping syndrome in this population of patients are 
available132.
57: Constant enteral nutrition via a feeding jejunos-
tomy can be effective for the management of refractory 
dumping syndrome. 
•	 Statement not endorsed.
•	Overall agreement 55%: A+ 25%, A 30%, A− 15%, 
D− 10%, D 20%, D+ 0%.
•	Grade C.
58: Continuous enteral feeding via a gastrostomy 
tube can be effective for the management of dumping 
syndrome after Nissen fundoplication. 
•	 Statement not endorsed.
•	Overall agreement 40%: A+ 15%, A 25%, A− 20%, 
D− 20%, D 20%, D+ 0%.
•	Grade C.
Evidence supporting statements 57 and 58 is scarce, 
and is mainly derived from a few case reports, including 
Table 4 | Summary of studies evaluating somatostatin analogues in dumping syndrome
Study n Treatment Result
Short- acting somatostatin analogues
Hopman 
et al.122
12 Octreotide 50 µg versus placebo prior 
to OGTT
Improved symptoms of dumping syndrome and suppression of postprandial rise in pulse 




10 Octreotide 50 µg versus 100 µg versus 
placebo prior to OGTT
Reduced symptoms of early dumping syndrome and abolished symptoms of late 
dumping syndrome; suppression of early dumping- associated changes in haematocrit 
and pulse rate; inhibition of hypoglycaemia
Tulassay 
et al.127
8 Octreotide 50 µg versus placebo prior 
to OGTT
Suppression of rise in pulse rate and haematocrit; suppression of rise in plasma levels of 
vasoactive intestinal polypeptide; inhibition of postprandial hypoglycaemia; inhibition 
of rise in plasma levels of insulin and gastric inhibitory polypeptide
Geer 
et al.128
10 Octreotide 100 µg versus placebo prior 
to a dumping provocative meal
Prevention of development of symptoms of dumping syndrome and diarrhoea; 
prevention of late hypoglycaemia and of the rise in plasma levels of glucose, glucagon, 




6 Octreotide 100 µg versus placebo prior 
to a dumping provocative meal
Prevention of symptoms of dumping syndrome; induction of migrating motor complex 
phase 3 in the small intestine; less postprandial intestinal motor activity
Gray 
et al.130
9 Octreotide 100 µg versus placebo prior 
to a dumping provocative meal
Suppression of rise in pulse rate; inhibition of insulin release; prevention of 
hypoglycaemia; inhibition of symptoms of dumping syndrome
Hasler 
et al.131
8 Octreotide 50 µg versus placebo prior 
to OGTT
Suppression of rise in pulse rate; inhibition of symptoms of dumping syndrome and 
diarrhoea; no influence on change in haematocrit; inhibition of insulin release; 
prevention of hypoglycaemia; no influence on gastric emptying rate
Arts et al.17 30 Octreotide 50 µg prior to OGTT Suppression of rise in pulse rate and haematocrit; inhibition of postprandial 
hypoglycaemia; inhibition of rise in plasma levels of insulin; improvement of symptoms 
of early and late dumping syndrome
Deloose 
et al.68
9 Crossover placebo or pasireotide 
300 µg for 2 weeks
Inhibition of postprandial hypoglycaemia; slowed gastric emptying rate
Tack 
et al.86
43 3- month dose- escalation study with 
pasireotide 50–200 µg (subcutaneous) 
followed by extension with monthly 
long- acting 10 mg or 20 mg injections
Improvement of symptoms of late and early dumping syndrome and signs on the OGTT
Long- acting somatostatin analogues
Arts et al.17 30 Octreotide long- acting release 20 mg 
(intramuscular)
Suppression of rise in pulse rate and haematocrit; inhibition of postprandial 
hypoglycaemia; inhibition of rise in plasma levels of insulin; improvement of symptoms 




24 Crossover study with placebo or 
lanreotide 90 mg (intramuscular)
Improvement of symptoms of early but not late dumping syndrome.
OGTT, modified oral glucose tolerance test.
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symptoms of dumping syndrome after Nissen fundo-
plication1,133. In a few case reports, insertion of a gas-
trostomy tube into the remnant stomach after RYGB 
reversed neuroglycopenic symptoms70,134. This treatment 
option can only be considered for severe refractory cases 
as it is invasive and as symptoms might improve with 
time (see subsequent section).
59: Conservative management approaches should be 
pursued before attempting surgical re- intervention as 
patients with dumping syndrome might experience 
symptomatic improvement over time. 
•	 Statement endorsed.
•	Overall agreement 85%: A+ 65%, A 20%, A− 10%, 
D− 0%, D 5%, D+ 0%.
•	Grade B.
60: Patients with severe hypoglycaemia after RYGB who 
do not respond adequately to dietary modification and 
pharmacologic intervention should be considered for 
surgical re- intervention. 
•	 Statement not endorsed.
•	Overall agreement 70%: A+ 40%, A 30%, A− 25%, 
D− 5%, D 0%, D+ 0%.
•	Grade C.
61: The association between hypoglycaemia after RYGB 
and nesidioblastosis that might result in serious and 
refractory neuroglycopenic symptoms might be resolved 
with pancreatic resection (distal, subtotal and total pan-
creatomies — distal pancreatectomy with or without 
splenectomy is the most common). 
•	 Statement not endorsed.
•	Overall agreement 45%: A+ 15%, A 30%, A− 30%, 
D− 20%, D 5%, D+ 0%.
•	Grade C.
62: The proportion of patients with symptom resolution 
is generally higher for gastric bypass reversal or gastric 
pouch restriction than for pancreatic resection. 
•	 Statement not endorsed.
•	Overall agreement 50%: A+ 15%, A 35%, A− 20%, 
D− 20%, D 5%, D+ 5%.
•	Grade C.
No real data are available on the natural history 
of dumping syndrome, and hence whether patients 
improve over time has not been established. A number 
of studies have reported on surgical re- intervention in 
the treatment of severe hypoglycaemia in patients after 
RYGB using a variety of surgical techniques (such as 






Dumping syndrome is a complication of oesophageal or gastric surgery that can comprise both early and late dumping 
syndrome symptoms
1–6 Grade B
Early dumping syndrome is the typical and most frequent manifestation of dumping syndrome and can occur in isolation or 
in association with late symptoms
4–6 Grades 
A and B
Dumping syndrome affects quality of life and can be associated with weight loss 7 and 8 Grade B
Symptoms of early dumping syndrome are driven by rapid delivery of nutrients to the small bowel, which triggers release of 
several gastrointestinal hormones, including vasoactive agents, incretins and glucose modulators
9–13 Grade B
Hypoglycaemia is the main symptom of late dumping syndrome, and is driven by a hyperinsulinaemic response and GLP1 
release
14 and 15 Grades 
A and B
Dumping syndrome can contribute to weight loss after bariatric surgery 16 and 17 Grade B
Dumping syndrome should be suspected based on the clinical history , but currently available dumping questionnaires have 
no proven diagnostic value
19–26 Grades 
B and C
Spontaneous hypoglycaemia below 2.8 mmol/l (50 mg/dl) is suggestive of late dumping syndrome 27 Grade B
A modified oral glucose tolerance test is a useful diagnostic test for dumping syndrome. The test is considered positive 
for early dumping syndrome in case of an early (30 min) increase in haematocrit >3% or in pulse rate >10 bpm. The test is 
considered positive for late dumping syndrome in case of late (60–180 min after ingestion) hypoglycaemia (<50 mg/dl)
33–39 Grades 
B and C
The value of continuous glucose monitoring for diagnosing dumping syndrome has not been established 30 and 31 Grade C
Mixed meal tests are not considered superior to the modified glucose tolerance test, and gastric emptying tests have no 
established value in diagnosing dumping syndrome
40–42 Grades 
B and C
Dietary intervention, with elimination of rapidly absorbable carbohydrates, is the first- line treatment approach for dumping 
syndrome. Patients are also advised to consume high fibre and protein- rich foods, eaten slowly and chewed well
43–47 Grades 
B and C
Agents that increase meal viscosity have no established value in the management of dumping syndrome 48 Grade B
Acarbose is effective for the treatment of dumping syndrome symptoms, especially symptoms of late dumping syndrome 50 and 51 Grade B
Diazoxide has no established value for the treatment of dumping syndrome 52 Grade C
Somatostatin analogues are effective for the treatment of dumping syndrome. The short- acting analogues have greater 
efficacy but require multiple injections
53–56 Grade B
Continuous enteral or gastric feeding has no established value for the treatment of dumping syndrome 57 and 58 Grade C




GLP1, glucagon- like peptide 1.
NAtuRe RevIeWs | EnDoCRinoloGy
e v i d e n c e - B a s e d  g u i d e l i n e s
  volume 16 | August 2020 | 461
bypass reversal, pouch restriction and interposed intes-
tinal loops), with variable outcomes135–145. In one report, 
three patients with dumping syndrome and refractory 
hypoglycaemia had insufficient benefit of the reversal of 
their gastric bypass and they ultimately required partial 
pancreatectomy for control of neuroglycopenia117.
Indeed, pancreatic nesidioblastosis (a hyperplasia 
of islet cells that is potentially driven by elevated secre-
tion of GLP1) has been implicated in the pathogenesis 
of refractory hypoglycaemia; on the basis of several 
reported cases, subtotal pancreatectomy is the suggested 
treatment117,137,146–150. Other studies, however, claim that 
hyperinsulinaemic hypoglycaemia after gastric bypass 
surgery is not accompanied by islet hyperplasia or 
increased β- cell turnover, and hence that nesidioblasto-
sis is not established as the cause of late hypoglycaemia 
in these patients151. In fact, the available evidence sup-
ports a functional hyperinsulinism driven at least in part 
by high levels of glucose and incretin after meals rather 
than increased islet cell mass, thereby questioning the 
concept of nesidioblastosis151,152.
A meta- analysis of results from 14 studies that 
enrolled a total of 75 patients who underwent surgical 
interventions for severe hypoglycaemia after RYGB 
reported hypoglycaemia resolution in 67% of patients 
after pancreatic resection, 76% after gastric bypass 
reversal and 82% after pouch restriction147. However, a 
follow- up study by the Mayo Clinic group showed that 
25% of patients not responding to other therapeutic 
measures also experienced no benefit from partial pan-
createctomy and that, with time, recurrences of hypo-
glycaemia also occurred, further questioning the benefit 
of these interventions152. Thus, randomized controlled 
trials are needed to determine the true efficacy of gastric 
bypass reversal or gastric pouch versus subtotal or total 
pancreatic resection.
Recommendations
On the basis of the statements that generated consen-
sus, a number of recommendations can be made for 
managing patients with dumping syndrome, which 
are summarized in Table 5. There is good agreement 
on definition, symptom pattern and underlying patho-
physiological mechanisms. The pathophysiological con-
cepts of dumping syndrome are summarized in Fig. 1. 
However, the Delphi process also identified several areas 
of uncertainty, which require further research.
Dumping syndrome might contribute to the weight 
loss that occurs after bariatric surgery (statements 16 
and 17). However, there is some controversy about 
whether symptoms of dumping syndrome after bari-
atric surgery can be useful for the patient’s aware-
ness of unwanted food effects and hence contribute to 
the weight loss (statement 17)11,55,60. Furthermore, the 
literature shows no evidence that dumping syndrome 
improves or might contribute favourably to the weight 
loss after bariatric surgery (statement 17)11,55,60. More-
over, dumping syndrome impairs the quality of life 
of patients so it should be considered a deleterious 
complication in these patients. Nevertheless, additional 
prospective studies are warranted to further clarify this 
issue. The nature of the putative entity of ‘idiopathic 
dumping syndrome’ in patients who did not undergo 
surgery, which is characterized by rapid gastric empty-
ing and associated symptoms, also lacks consensus 
(statement 18).
In terms of diagnosis, the available dumping syn-
drome severity questionnaires are not considered 
Diet
Agents that increase meal 








• Release of vasoactive agents
• Release of incretins











Rapid absorption of glucose
Acarbose
Fig. 1 | Pathophysiology and therapeutic targets in dumping syndrome. The pathophysiological flow chart of dumping 
syndromes is presented in purple, with the main features of early and late dumping syndromes presented in blue. 
Therapeutic agents that increase meal viscosity (such as guar gum, pectin and glucomannan) have no clear evidence of 
efficacy (yellow). By contrast, endorsed evidence of efficacy is available for the use of diet modifications, acarbose and 
somatostatin analogues (pink).
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reli able enough to aid in the diagnostic process (state-
ments 21–27). Furthermore, all of these questionnaires 
are thought to lack sensitivity to treatment interventions, 
indicating the need for a specific patient- reported out-
come questionnaire to be developed for dumping syn-
drome. There is agreement that the modified OGTT 
is the preferred diagnostic method (statement 33), 
and diagnostic parameters for early and late dumping 
syndrome are well established (statements 34–36). The 
same glycaemia level cut- off (50 mg/dl) is proposed for 
spontaneous glycaemia levels and for late hypoglycaemia 
during the modified OGTT for supporting the diagnosis 
of dumping syndrome (statements 28, 29, 35 and 36). 
However, the reproducibility and sensitivity of the mod-
ified OGTT are not well established (statements 37–39). 
The value of continuous glucose monitoring in the diag-
nosis and management of dumping syndrome needs 
further research (statements 29, 31 and 32) and the 
mixed meal test is not considered a standard for diag-
nosis (statement 40). No diagnostic value is attributed 
to gastric emptying tests (statements 41 and 42).
There is agreement that a dietary approach, focus-
ing on low- volume meals with elimination of rapidly 
absorbable carbohydrates, protein- rich and high- fibre 
foods and delay of fluid intake, is the preferred ini-
tial approach for the treatment of dumping syndrome 
(statements 43–47). The pathophysiological basis for 
dumping syndrome treatments is summarized in Fig. 1. 
In patients who do not respond to diet modifications, 
pharmacotherapy is advocated, and the use of acarbose 
is supported (statements 49 and 50), especially for late 
dumping syndrome; however, the effects of acarbose in 
early dumping syndrome are unclear (statement 51). 
The Delphi panel did not support the use of agents 
that increase meal viscosity or diazoxide (statements 
48 and 52). In patients who do not respond to diet 
modifications or acarbose, somatostatin analogues 
are supported for their ability to control symptoms of 
both early and late dumping syndrome (statement 53). 
Short- acting analogues are considered superior to 
long- acting forms, but the need for repeated injections 
with short- acting agents is a limiting factor (statements 
54–56). In patients who do not respond to treatment, the 
value of continuous enteral feeding and especially of sur-
gical re- intervention and pancreatic resection is uncer-
tain (statements 56–58 and 60–62) and a conservative, 
non- surgical approach is recommended (statement 59). 
A diagnostic and therapeutic algorithm based on the 
Delphi process is shown in box 3.
Conclusion
Dumping syndrome is a prevalent but probably under- 
recognized complication of oesophageal and gastric sur-
gery, including bariatric interventions. To date, there are 
no established guidelines on the diagnosis and manage-
ment of dumping syndrome, and hence we organized a 
Delphi consensus process to establish the current state 
of knowledge, to provide guidance to clinicians and 
identify areas requiring future research.
The Consensus Group reached consensus on several 
aspects, including the definition, symptom pattern and 
presumed underlying pathophysiology. Clinical aware-
ness and modified OGTT are the key methods for making 
a diagnosis of dumping syndrome. In addition to dietary 
measures, acarbose and somatostatin analogues are well 
accepted treatment modalities. The consensus process 
Box 3 | Diagnostic and treatment algorithm for dumping syndrome
•	the presence of symptoms suggestive of early or late dumping 
syndrome in a patient who has undergone oesophageal or gastric 
surgery should raise clinical suspicion. Patients often mention the need 
to lie down after meals due to profound weakness.
•	standard diagnostic evaluation (using endoscopy and imaging, for 
instance) might be necessary to exclude other reasons for the symptoms 
(such as postoperative strictures, adhesions and insulinoma).
•	the modified oral glucose tolerance test is the preferred diagnostic 
method to confirm the diagnosis of dumping syndrome, and diagnostic 
parameters for early dumping syndrome are well established: an increase 
in haematocrit >3% at 30 min or an increase in pulse rate >10 bpm after 
30 min. late hypoglycaemia is another indicator of dumping syndrome; 
there is agreement on a cut- off of 50 mg/dl and not of 60 mg/dl.
•	similarly, there is no consensus on the nadir spontaneous glycaemia 
level that supports the diagnosis of dumping syndrome.
•	Dietary measures, focusing on low- volume meals with elimination of 
rapidly absorbable carbohydrates and delay of fluid intake, are the 
preferred initial approach.
•	In patients who do not respond to diet modification, the use of acarbose 
is recommended, especially for late dumping syndrome, but with an 
unclear effect on early dumping syndrome.
•	In patients who do not respond to diet and/or acarbose, somatostatin 
analogues can control symptoms of both early and late dumping 
syndrome. It is unclear whether short- acting analogues are superior to long- acting formulations.
•	In patients who do not respond to treatments, the value of continuous enteral feeding and especially of surgical 
re- intervention and pancreatic resection is uncertain and a conservative approach is recommended.
Suspected dumping syndrome
in a patient with a history of
gastric or oesophageal surgery
Use endoscopy and imaging to exclude the
possibility that abnormalities other than
dumping syndrome underlie the symptoms
Confirm diagnosis by modified oral
glucose tolerance test or measurement
of spontaneous hypoglycaemia
Dietary measures
Consider acarbose (for late dumping syndrome) 
or consider somatostatin analogues
Carefully consider
experimental approaches
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also identified areas in need of further research, such as 
the development and evaluation of diagnostic and out-
come questionnaires, agreement of threshold glycaemia 
levels for reliable diagnosis, evaluation of the therapeu-
tic efficacy of acarbose for symptoms of early dumping 
syndrome and assessment of the relative efficacy of 
short- acting versus long- acting somatostatin analogues. 
The role of mixed meal tests, gastric emptying tests, 
continuous enteral nutrition and surgical interventions 
for dumping syndrome also need further evaluation.
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